Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…
EnvisionJune 10, 2023
Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…
EnvisionMarch 3, 2023
Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…
EnvisionJanuary 27, 2022
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
EnvisionFebruary 10, 2021
Today, CB Insights China published, for the first time, a top list of RNA biotech…
EnvisionMay 19, 2020
Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical…
EnvisionJuly 11, 2018
Today, an article entitled "Small activating RNA induced expression of VHL gene in renal cell…
EnvisionFebruary 7, 2018
The 6th RNAi China conference was held on October 10th and 11th at Kunshan as…
EnvisionOctober 11, 2017
Springer•Nature published a book edited by Ractigen’s founder, Dr. Long-Cheng LI and entitled “RNA Activation”.…
EnvisionJuly 12, 2017
